Memantine Shows Promise Against Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxPasritamig in Late-Line Prostate Cancer: From Early Findings to the KLK2-comPAS Trial
/in Clinical Trial, Metastatic, Phase 3/by MaxFDA Clears First Therapeutic Trial of Lead-212 Radioligand AB001 in Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxUPDATE: Phase 2 Results for 177Lu-DGUL Look Very Promising
/in Clinical Trial, Metastatic, Phase 2/by MaxAnother Trial Supports Low-Dose Abiraterone Acetate in mCRPC
/in Clinical Trial, Metastatic, Phase 2/by MaxThis study, published in JCO Global Oncology and focused on abiraterone acetate (AA), a drug used to treat metastatic castration-resistant prostate cancer, suggests that a smaller dose of AA is as effective as the standard dose (we already talked about another study pointing in the same direction in Singapore, but this sample is bigger). The […]
IND Required for ITC-6146RO for Solid Tumors Overexpressing the B7-H3 Protein
/in Clinical Trial, Metastatic, Phase 1/by MaxOn August 29, 2025, a clinical trial plan (Investigational New Drug application) was submitted to the Ministry of Food and Drug Safety (MFDS) of South Korea to initiate phase 1 clinical trials for ITC-6146RO. ITC-6146RO is an antibody-drug conjugate (ADC) designed to target solid tumors overexpressing the B7-H3 protein, such as metastatic castration-resistant prostate cancer […]
Anti-PD-L1 Therapy Shows Promise for MMR-Deficient Metastatic Prostate Cancer
/in Clinical Trial, Metastatic/by MaxPhase 2 Trial: Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response via Modulation of Androgen Receptor (SPIDERMAN)
/in Clinical Trial, Metastatic, Phase 2/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- GSK5764227: An Antibody-Drug Conjugate Targeting B7-H3 Enters Phase 1/2 Trial December 12, 2025
- MHB048C: A New PSMA-Targeted Therapy for Advanced Solid Tumors December 12, 2025
- Logic-gated DARPins, a Promising Advancement in Immune Therapy for Solid Tumors December 11, 2025
- CONVERT‑HB1: a Phase 2 Trial About Prostate Directed Treatment After Systemic Treatment in mHSPC December 11, 2025